Cyber Arms Dealer Exploits New iPhone Software Vulnerability, Watchdog Says

A cyber surveillance company based in Israel developed a tool to break into Apple iPhones with a never-before-seen technique that has been in use since February, internet security watchdog group Citizen Lab said Monday.

The discovery is important because of the critical nature of the vulnerability, which requires no user interaction and affects all versions of Apple’s iOS, OSX, and watchOS, except for those updated Monday.

The vulnerability developed by the Israeli firm, named NSO Group, defeats security systems designed by Apple in recent years.

Apple said it fixed the vulnerability in Monday’s software update, confirming Citizen Lab’s finding. An Apple spokesperson declined to comment regarding whether the hacking technique came from NSO Group.

In a statement to Reuters, NSO did not confirm or deny that it was behind the technique, saying only that it would “continue to provide intelligence and law enforcement agencies around the world with life-saving technologies to fight terror and crime.”

Citizen Lab said it found the malware on the phone of an unnamed Saudi activist and that the phone had been infected with spyware in February. It is unknown how many other users may have been infected.

The intended targets would not have to click on anything for the attack to work. Researchers said they did not believe there would be any visible indication that a hack had occurred.

The vulnerability lies in how iMessage automatically renders images. IMessage has been repeatedly targeted by NSO and other cyber arms dealers, prompting Apple to update its architecture. But that upgrade has not fully protected the system.

“Popular chat apps are at risk of becoming the soft underbelly of device security. Securing them should be top priority,” said Citizen Lab researcher John Scott-Railton.

The U.S. Cybersecurity and Infrastructure Security Agency had no immediate comment.

Explosion in attacks

Citizen Lab said multiple details in the malware overlapped with prior attacks by NSO, including some that were never publicly reported. One process within the hack’s code was named “setframed,” the same name given in a 2020 infection of a device used by journalists at Al Jazeera, the researchers found.

“The security of devices is increasingly challenged by attackers,” said Citizen Lab researcher Bill Marczak.

A record number of previously unknown attack methods, which can be sold for $1 million or more, have been revealed this year. The attacks are labeled “zero-day” because software companies had zero days’ notice of the problem.

New cybersecurity focus

Along with a surge in ransomware attacks against critical infrastructure, the explosion in such attacks has stoked a new focus on cybersecurity in the White House as well as renewed calls for regulation and international agreements to rein in malicious hacking.

As previously reported, the FBI has been investigating NSO, and Israel has set up a senior inter-ministerial team to assess allegations that its spyware has been abused on a global scale.

Although NSO has said it vets the governments it sells to, its Pegasus spyware has been found on the phones of activists, journalists and opposition politicians in countries with poor human rights records.

Source: Voice of America

Britain to Offer COVID-19 Vaccines to 12-to-15-year-Olds

Britain’s chief medical officer (CMO), Professor Chris Whitty, recommended Monday that children between the ages of 12 and 15 be offered the COVID-19 vaccine, saying they would benefit from reduced disruption to their education.

More than a week ago, Britain’s Joint Committee on Vaccination and Immunization, the panel that advises British health departments on immunization policies, issued a statement saying the “margin of benefit” to inoculating children of those ages was too small for them to recommend the government do so.

But Monday, Whitty, along with his counterparts from Scotland, Wales and Northern Ireland, told reporters they are recommending to their respective health ministers that the age group be given a single dose of the Pfizer-BioNTech vaccine. They have yet to decide on whether to give the students a second dose.

Whitty stressed the vaccinations should be “an offer,” not a mandate, adding, “We do not think this is a panacea. This is not a silver bullet … but we think it is an important and potentially useful additional tool to help reduce the public health impacts that come through educational disruption.”

Whitty said the CMOs have shared their recommendations with their ministers, and it is now up to the ministers to decide how to respond.

The United States, Israel and some European countries have rolled out vaccinations to children more broadly, putting pressure on the British government to follow suit.

Britain has experienced more than 134,000 deaths from COVID-19, and a rapid start to its immunization rollout has slowed, with 81% of those over 16 receiving two vaccine doses.

Source: Voice of America

ANGOLA AND UAE PREPARE COOPERATION AGREEMENTS

Luanda – Several cooperation agreements between Angola and the United Arab Emirates (UAE) in the sectors of air and road transport, agriculture, mining, energy and trade are due to be signed this year, as part of the existing partnership between the two countries.

With this purpose, the President of the Republic, João Lourenço, received in audience, this Sunday, the UAE Minister of State for Foreign Affairs, Sheik Shakbbot Nahayan Mabarak Al-Nahyan.

Speaking to the press at the end of the meeting, Angolan Foreign Minister, Téte António, who attended the audience, said that the two countries are working to translate actions into practice.

“What is intended is that investment from the United Arab Emirates happens in various sectors of the Angolan economy. It will be a salutary partnership, in the scope of public investments,” he assured.

Téte António said that before the end of the current year, a high-level Angolan delegation would visit the United Arab Emirates with the aim of signing the cooperation agreements.

Angola and the United Arab Emirates cooperate in the oil and gas, mining, trade and investment, energy, defence, transport, agriculture, fishing, banking, telecommunications and finance and tax sectors.

The United Arab Emirates is located in the southeast of the Arabian Peninsula and borders Oman and Saudi Arabia.

Source: Angola Press News Agency

COVID-19: ANGOLA REPORTS 104 NEW CASES, 12 DEATHS

Luanda- Angola has registered, in the last 24 hours, 104 new cases, 12 deaths and the recovery of 30 patients.

According to the figures released, 70 cases were diagnosed in Luanda, 17 in Huila, 5 in Namibe, 3 in Benguela, 3 in Uige, 2 in Bié, 2 in Moxico, 1 in Cunene and 1 in Lunda Norte.

The list includes 52 male and 52 female patients whose ages range from 1 to 88 year old.

According to the data, deaths were reported in the provinces of Huila, with 5, Luanda with 4, Bié with 2 and Namibe with 1.

Among the recovered patients, 9 reside in Namibe, 7 in Huila, 6 in Moxico, 5 in Huambo, 2 in Luanda and 1 in Benguela.

The laboratories processed, in the last 24 hours, 1,652 samples.

There are 270 patients in the hospitalisation centres, while the institutional quarantine centres host 195 citizens.

There are 1,881 contacts of positive cases under medical surveillance.

Angola has 50,446 cases, with 1,339 deaths, 44,652 recovered and 4,455 active. Of the active cases, 23 are critical, 43 serious, 145 moderate, 61 light and 4.183 asymptomatic.

Source: Angola Press News Agency

COVID-19: ANGOLA RECEIVES 500,000 DOSES OF SINOPHARM VACCINE

Luanda – Angola received, this Sunday, 500,000 doses of Sinopharm vaccine against Covid-19, as part of the ongoing vaccination process in the country.

According to the Minister of Health, Sílvia Lutucuta, this is a consignment acquired by the government to reinforce the individual and collective protection measures of the citizens.

“We must fully comply with simple measures, such as wearing the mask correctly, washing hands frequently, avoiding gatherings, promoting distancing between people, because we have community circulation of the virus at national level,” warned Silvia Lutucuta.

Silvia Lutucuta announced the arrival, in the next few days, of another 480,000 doses of vaccine from Sinopharm.

She appealed to the population aged 18 or over to go to the vaccination posts closest to their area of residence because the vaccine is free and safe.

According to the Cabinet minister, the government vaccination target is to immunized at least 60 per cent of the eligible population, a total of 15.8 million people.

Since the beginning of the vaccination process in March this year, more than 2 million Angolans have already been vaccinated.

AstraZeneca, Sinopharm, Sputnik and Johnson& Johnson vaccines are being administered in the country.

Source: Angola Press News Agency

FOOTBALL: PETRO DE LUANDA DRAW WITH FOVU IN CAMEROON

Luanda – The team of Petro de Luanda have drawn against Fovu Baham of Cameroon, by 2-2, in the first “leg” of the access to the group stage of the African Champions League of football, played Sunday at Omnisports Stadium.

The Angolan team, who conceded the first goal in the 14th minute through Alexander Nsangue, restored the draw in the 19th minute through Tiago Azulão.

The Angolan team had the advantage (2-1) in the first half (45+1), with Jaredi’s goal, but let the victory slip away when Ikpeme scored the equaliser in the last minute (90min.).

The second “leg” will take place between next 17th and 19th September, in Luanda.

Source: Angola Press News Agency

INTERCLUB BEAT TANZANIA MAFUNZO

Luanda – Interclub started the African Confederations Cup in the best way by beating Mafunzo FC of Tanzania, 1-0, in the first “leg” of the qualifiers for access to the group stage, played today, Sunday, at Amaan Stadium, in that country.

Despite playing on the opponents’ field, the single goal of the Angolan team was scored by Paty, in the 29th minute.

The second leg will take place between the 17th and 19th September, in Luanda.

Guided by the Spanish-Brazilian coach, Beto Bianchi, the “police” team has as main goal to reach the group stage.

Source: Angola Press News Agency

Adagio Therapeutics annonce l’élargissement de la population de patients participant à l’essai clinique mondial de phase 2/3 de l’ADG20 pour la prévention de la COVID-19

Le Comité de surveillance des données indépendant approuve l’élargissement aux adolescents ainsi qu’aux femmes enceintes et allaitantes sur la base des données d’innocuité et de tolérance de la partie de pré-inclusion de phase 2

WALTHAM, Massachusetts, 10 sept. 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., une société biopharmaceutique au stade clinique axée sur la découverte, le développement et la commercialisation de solutions à base d’anticorps pour les maladies infectieuses présentant un potentiel pandémique, a annoncé aujourd’hui que le Comité indépendant de surveillance des données (IDMC) a formulé une recommandation visant à étendre le recrutement dans l’essai de phase 3 dans le cadre de l’essai EVADE de phase 2/3 de l’ADG20 pour la prévention de la COVID-19, afin d’inclure des adolescents et des femmes enceintes ou allaitantes. ainsi que pour réduire le délai de surveillance post-injection spécifié dans le protocole. Les évaluations de l’IDMC sont basées sur son examen des données d’innocuité et de tolérance sans insu provenant de 200 participants inscrits dans la partie de « pré-inclusion » de phase 2 de l’essai. Adagio n’a toujours pas connaissance des données et prévoit de mettre en œuvre les recommandations de l’IDMC lors de la phase 3 de l’essai. EVADE est mené à l’échelle mondiale, y compris dans les régions où la prévalence des variants du SARS-CoV-2 est élevée, afin d’évaluer la capacité d’une dose intramusculaire unique de l’ADG20 à prévenir la COVID-19 dans les contextes de pré et post-exposition.

« Au vu du besoin urgent de traitements supplémentaires et d’options préventives pour la COVID-19, en particulier dans les populations vulnérables, nous sommes ravis qu’une évaluation indépendante des données d’innocuité provenant de la partie de pré-inclusion d’EVADE ait soutenu l’inclusion d’adolescents et de femmes enceintes ou allaitantes dans la prochaine phase de l’étude », a déclaré Lynn Connolly, M.D., Ph.D., directrice médicale d’Adagio. « Sur la base de l’activité puissante et large de l’ADG20 dans les études non cliniques, ainsi que de sa demi-vie prolongée et de sa facilité d’administration, nous pensons que cet anticorps a le potentiel de devenir une option prophylactique de choix pour la COVID-19, en particulier pour les groupes vulnérables tels que les enfants et les personnes immunodéprimées, pour lesquels les options sont actuellement limitées ou inexistantes. »

L’essai EVADE est un essai clinique mondial, multicentrique, en double aveugle et contrôlé par placebo évaluant l’ADG20 dans deux cohortes indépendantes. La première cohorte (prophylaxie post-exposition) est destinée à évaluer l’innocuité et l’efficacité de l’ADG20 par rapport au placebo dans la prévention de la COVID-19 suite à une exposition à une personne atteinte d’une infection au SARS-CoV-2 confirmée en laboratoire. La deuxième cohorte (prophylaxie pré-exposition) est destinée à évaluer l’efficacité et l’innocuité de l’ADG20 par rapport au placebo chez les individus présentant un risque accru d’infection par le SARS-CoV-2 en raison de leurs situations professionnelles, de leurs conditions de logement ou de leurs loisirs, ainsi que chez les individus présentant un risque accru de mauvaise réponse vaccinale, y compris les personnes dont le système immunitaire est affaibli ou atteintes d’autres co-morbidités. Le critère principal d’efficacité dans les deux cohortes est la prévention de la COVID-19 symptomatique confirmée en laboratoire. Pour tout complément d’information sur l’essai EVADE, veuillez consulter le site https://clinicaltrials.gov/ct2/show/NCT04859517.

Le programme de développement clinique pour l’ADG20 comprend deux essais supplémentaires : l’essai clinique de phase 1 en cours sur l’ADG20 chez des volontaires en bonne santé et l’essai STAMP en cours évaluant l’ADG20 en tant que traitement pour les personnes à haut risque atteintes d’une forme légère ou modérée de la COVID-19 (voir clinicaltrials.gov).

À propos de l’ADG20
L’ADG20, un anticorps monoclonal ciblant la protéine spike du SARS-CoV-2 et des coronavirus connexes, est en cours de développement aux fins de la prévention et du traitement de la COVID-19, la maladie provoquée par le SARS-CoV-2. L’ADG20 a été conçu et élaboré en vue d’offrir de puissantes et vastes capacités de neutralisation du SARS-CoV-2 et des autres sarbecovirus du clade 1 permettant de cibler un épitope bien conservé dans le domaine de fixation du récepteur. L’ADG20 exerce une puissante activité neutralisante contre la souche originale du SARS-CoV-2 et tous ses variants préoccupants connus. L’ADG20 pourrait avoir un impact sur la réplication virale et la maladie subséquente grâce à de multiples mécanismes d’action, notamment le blocage direct de l’entrée virale dans la cellule hôte (neutralisation) et l’élimination des cellules hôtes infectées par le biais d’une activité médiée par Fc des cellules effectrices de l’immunité innée. L’ADG20 est formulé à concentrations élevées, ce qui permet son administration intramusculaire, et a été conçu pour avoir une longue demi-vie, dans le but d’offrir une protection immédiate et durable. Adagio fait progresser l’ADG20 grâce à de multiples essais cliniques à l’échelle mondiale.

À propos d’Adagio Therapeutics
Adagio est une société biopharmaceutique au stade clinique axée sur la découverte, le développement et la commercialisation de solutions à base d’anticorps pour les maladies infectieuses présentant un potentiel pandémique. Le portefeuille d’anticorps de la société a été optimisé grâce aux capacités de pointe d’Adimab en matière d’ingénierie d’anticorps et est conçu pour fournir aux patients et aux cliniciens une combinaison inégalée de puissance, d’ampleur, de protection durable (grâce à l’extension de la demi-vie), de faisabilité de fabrication et de prix abordable. Le portefeuille d’anticorps anti-SARS-CoV-2 d’Adagio comprend plusieurs anticorps fortement neutralisants non concurrents dotés d’épitopes de liaison distincts, dirigés par l’ADG20. Adagio a conclu avec des sous-traitants tiers un contrat portant sur des capacités de fabrication pour la production de l’ADG20 jusqu’à l’achèvement des essais cliniques et, en cas d’approbation par les autorités réglementaires, jusqu’au lancement commercial initial. Pour plus d’informations, rendez-vous sur notre site www.adagiotx.com.

Contacts :
Contact auprès des médias :
Dan Budwick, 1AB
Dan@1abmedia.com

Contact auprès des investisseurs :
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

Adagio Therapeutics Anuncia Expansão da População de Pacientes no Ensaio Clínico Global de Fase 2/3 do ADG20 para Prevenção da COVID-19

Comitê Independente de Monitoramento de Dados Apoia a Expansão para Adolescentes e Gestantes e Mulheres Amamentando com Base em Dados de Segurança e Tolerabilidade da Fase 2 de Lead-In

WALTHAM, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — A Adagio Therapeutics, Inc., uma empresa biofarmacêutica de estágio clínico focada na descoberta, desenvolvimento e comercialização de soluções baseadas em anticorpos para doenças infecciosas com potencial pandêmico, anunciou hoje que o comitê independente de monitoramento de dados (IDMC) para o ensaio de EVADE da Fase 2/3 do ADG20 para a prevenção da COVID-19 fez uma recomendação para a expansão da inscrição no ensaio de Fase 3 para incluir adolescentes e mulheres grávidas ou lactantes, bem como para diminuir o tempo de monitoramento pós-injeção especificado pelo protocolo. As avaliações do IDMC têm por base a análise dos dados de segurança e tolerabilidade não cegos de 200 participantes inscritos na parte inicial da Fase 2 do estudo. A Adagio permanece cega em relação aos dados e planeja implementar as recomendações do IDMC para a parte da Fase 3 do estudo. A EVADE está sendo conduzida globalmente, inclusive em regiões onde há uma alta prevalência de variantes preocupantes do SARS-CoV-2, para avaliar a capacidade de uma dose única e intramuscular de ADG20 para prevenir a COVID-19 em ambos os cenários pré e pós-exposição.

“Dada a necessidade urgente de tratamento adicional e de opções preventivas para a COVID-19, particularmente em populações vulneráveis, estamos satisfeitos que uma avaliação independente dos dados de segurança da parte inicial da EVADE apoiou a inclusão de adolescentes e mulheres grávidas ou lactantes na próxima fase do estudo”, disse Lynn Connolly, M.D., Ph.D., diretora médica da Adagio. “Com base na atividade potente e ampla do ADG20 em estudos não clínicos, bem como em sua meia-vida prolongada e facilidade de administração, acreditamos que este anticorpo tenha o potencial de se tornar uma opção profilática preferida para COVID-19, particularmente para grupos vulneráveis, como crianças e imunocomprometidos, para os quais atualmente exista opções limitadas ou não disponíveis.”

O ensaio EVADE é um ensaio global clínico, multicêntrico, duplo-cego, controlado por placebo que avalia o ADG20 em duas coortes independentes. A primeira coorte (profilaxia pós-exposição) é projetada para avaliar a segurança e eficácia do ADG20 em comparação com o placebo para a prevenção da COVID-19 após a exposição a um indivíduo com infecção por SARS-CoV-2 confirmada laboratorialmente. A segunda coorte (profilaxia pré-exposição) é projetada para avaliar a eficácia e a segurança do ADG20 em comparação com o placebo em indivíduos com risco aumentado de infecção por SARS-CoV-2 devido a situações ocupacionais, de alojamento ou recreativas, e em indivíduos com risco aumentado de resposta vacinal ruim, incluindo indivíduos com sistema imunológico comprometido ou outras comorbidades. O desfecho primário da eficácia em ambas as coortes é a prevenção da COVID-19 sintomática confirmada laboratorialmente. Para mais informação sobre o ensaio EVADE, visite https://clinicaltrials.gov/ct2/show/NCT04859517.

O programa de desenvolvimento clínico para o ADG20 inclui dois ensaios adicionais: ensaio clínico de Fase 1 em andamento do ADG20 em voluntários saudáveis e ensaio STAMP em andamento de avaliação do ADG20 como tratamento para indivíduos de alto risco com COVID-19 leve ou moderado (consulte clinicaltrials.gov).

Sobre o ADG20
O ADG20, um anticorpo monoclonal direcionado à proteína Spike do SARS-CoV-2 e coronavírus relacionados, está sendo desenvolvido para a prevenção e tratamento da COVID-19, a doença causada pelo SARS-CoV-2. ADG20 foi projetado e criado para alta potência e ampla neutralização contra SARS-CoV-2 e sarbecovírus de clado 1 adicionais, direcionando-se a um epítopo altamente conservado no domínio de ligação ao receptor. O ADG20 exibe atividade neutralizante potente contra a cepa SARS-CoV-2 original, bem como todas as variantes preocupantes conhecidas. O ADG20 tem o potencial de impactar a replicação viral e a doença subsequente através de múltiplos mecanismos de ação, incluindo o bloqueio direto da entrada viral na célula hospedeira (neutralização) e a eliminação de células hospedeiras infectadas através da atividade efetora imune inata mediada por Fc. O ADG20 é formulado em altas concentrações, permitindo a administração intramuscular, e foi projetado para ter uma meia-vida longa, com o objetivo de fornecer proteção rápida e durável. A Adagio está avançando o ADG20 por meio de vários ensaios clínicos em uma base global.

Sobre a Adagio Therapeutics
A Adagio é uma empresa biofarmacêutica de estágio clínico focada na descoberta, desenvolvimento e comercialização de soluções com base em anticorpos para doenças infecciosas com potencial pandêmico. O portfólio de anticorpos da empresa foi otimizado com os recursos de engenharia de anticorpos líderes da indústria da Adimab, e foi criado para fornecer aos pacientes e médicos uma combinação de potência, amplitude, proteção durável (via extensão de meia-vida), capacidade de fabricação e acessibilidade. O portfólio de anticorpos contra SARS-CoV-2 da Adagio inclui múltiplos anticorpos amplamente neutralizantes não competitivos com epítopos de ligação distintos, liderados por ADG20. A Adagio adquiriu a capacidade de fabricação para a produção do ADG20 com fabricantes terceirizados através da conclusão de ensaios clínicos e, se aprovado pelas autoridades reguladoras, através do lançamento comercial inicial. Para mais informação, visite www.adagiotx.com.

Contatos:
Contato com a Mídia:
Dan Budwick, 1AB
Dan@1abmedia.com

Contato com o Investidor:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

Olives and Wine: Conagen Makes Accessible Antioxidant Hydroxytyrosol by Fermentation

Bedford, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Leveraging its robust phenolics platform, Conagen announced the expansion of the health ingredient portfolio of its commercial partner Blue California, with the successful scale-up and commercialization of the powerful natural antioxidant ingredient hydroxytyrosol.With its health-promoting properties, hydroxytyrosol is a phenylethanoid found in olives and wine. Most hydroxytyrosol is naturally found in the juice of olives, minorly in oil. Current hydroxytyrosol ingredients on the market are produced mainly through processed olive juice or are synthetic.

Conagen’s high-purity hydroxytyrosol is virtually colorless and odorless, making it ideal for formulating different products. The hydroxytyrosol is produced by using a cost-effective, sustainable natural fermentation process that has led to the filing of several patent applications, making it a preferred option compared to its olive juice concentrate and synthetic counterparts.

“Hydroxytyrosol is derived from one of our four small-molecule platforms.  The flexibility of our phenolics platform has enabled us to rapidly scale and commercialize hydroxytyrosol and other novel ingredients, highlighting our productive innovation engine and reliability as a strategic service partner,” said Vice President of Innovation, Casey Lippmeier, Ph.D. at Conagen.

Hydroxytyrosol has received increasing attention in the dietary supplement world due to its potent antioxidant and anti-inflammatory properties that contribute to the many health benefits of consuming olives. Preclinical and clinical studies demonstrate the positive effects of hydroxytyrosol on heart health and support healthy cholesterol levels.

“The Mediterranean diet is consistently rated as one of the healthiest diets, partially attributed to the use of olives,” Blue California’s Research, Science and Innovation Officer, Linda May-Zhang, Ph.D. “Hydroxytyrosol is one of the most potent antioxidants in olives, and research suggests the great promise of this molecule in healthy aging and potential immune support applications.”

In addition to immune health, emerging research suggests hydroxytyrosol supports heart health, metabolic health, bone health, brain health, and beauty.

Immune health will remain a top priority for consumers as 64% of global consumers are looking to improve their immunity over the next 12 months, reported by FMCG Gurus, Top Ten Trends for 2021, Dec. 2020.

“Conagen is unlocking unprecedented access to sustainable compounds which are only sparingly found in nature,” said Lippmeier. “We expect this and other related compounds will prove useful as cost-effective food or cosmetic ingredients or as additives to other products in which oxidation must be mitigated.”

Using precision fermentation, Conagen produces an extensive portfolio of ingredients, with a recent focus on phenolic antioxidants and natural preservatives such as Rosmarinic acid (Rosavel®)Capsaicin, and the recently announced p-Coumaric Acid (PCA). These ingredients add to a long list of health-promoting flavonoids such as Dihydroquercetin (DHQ), also known as Taxifolin.

Blue California is a provider of solutions and manufacturer/distributor of specialty ingredients, flavors, and fragrances and has a long-standing innovation partnership with Conagen. Conagen focuses on developing sustainable, nature-based ingredients that improve existing options in the market or represent completely novel ingredient solutions.

About Conagen

Conagen is a product-focused synthetic biology R&D company with large-scale manufacturing capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

About Blue California

Blue California is a vertically integrated technology company providing innovative ingredient solutions to global partners. With more than 20 years of innovation success, our ingredients are used in commercial products and applications in nutrition, personal care, healthy aging and wellness, functional food and beverage, and beauty. www.bluecal-ingredients.com

Attachment

Ana Arakelian
Conagen
+1.781.271.1588
ana.arakelian@conagen.com